| Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms PD Lister, DJ Wolter, ND Hanson Clinical microbiology reviews 22 (4), 582-610, 2009 | 2435 | 2009 |
| Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae PD Lister, CC Sanders Journal of antimicrobial chemotherapy 43 (1), 79-86, 1999 | 204 | 1999 |
| Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance DJ Wolter, ND Hanson, PD Lister FEMS microbiology letters 236 (1), 137-143, 2004 | 187 | 2004 |
| Clavulanate Induces Expression of the Pseudomonas aeruginosa AmpC Cephalosporinase at Physiologically Relevant Concentrations and Antagonizes the … PD Lister, VM Gardner, CC Sanders Antimicrobial agents and chemotherapy 43 (4), 882-889, 1999 | 140 | 1999 |
| Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital DJ Wolter, E Smith-Moland, RV Goering, ND Hanson, PD Lister Diagnostic microbiology and infectious disease 50 (1), 43-50, 2004 | 91 | 2004 |
| Pharmacodynamics of Trovafloxacin, Ofloxacin, and Ciprofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model PD Lister, CC Sanders Antimicrobial agents and chemotherapy 43 (5), 1118-1123, 1999 | 89 | 1999 |
| Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam PD Lister, AM Prevan, CC Sanders Antimicrobial agents and chemotherapy 41 (4), 721-727, 1997 | 80 | 1997 |
| Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae PD Lister, CC Sanders Journal of Antimicrobial Chemotherapy 47 (6), 811-818, 2001 | 79 | 2001 |
| Pharmacodynamics of Gatifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model: Impact of Area under the Curve/MIC Ratios on … PD Lister Antimicrobial agents and chemotherapy 46 (1), 69-74, 2002 | 74 | 2002 |
| Levofloxacin-Imipenem Combination Prevents the Emergence of Resistance among Clinical Isolates of Pseudomonas aeruginosa PD Lister, DJ Wolter Clinical infectious diseases 40 (Supplement_2), S105-S114, 2005 | 73 | 2005 |
| Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae PD Lister Diagnostic microbiology and infectious disease 44 (1), 43-49, 2002 | 67 | 2002 |
| Multiply-resistant pneumococcus: therapeutic problems in the management of serious infections. PD Lister European Journal of Clinical Microbiology & Infectious Diseases: Official …, 1995 | 67 | 1995 |
| Carbapenems in the USA: focus on doripenem PD Lister Expert Review of Anti-infective Therapy 5 (5), 793-809, 2007 | 64 | 2007 |
| Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies PD Lister, A Pong, SA Chartrand, CC Sanders Antimicrobial agents and chemotherapy 41 (9), 1926-1932, 1997 | 58 | 1997 |
| Pharmacodynamics of Moxifloxacin and Levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an In Vitro Pharmacodynamic Model PD Lister Clinical infectious diseases 32 (Supplement_1), S33-S38, 2001 | 57 | 2001 |
| Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype DJ Wolter, JA Black, PD Lister, ND Hanson Journal of Antimicrobial Chemotherapy 64 (2), 294-300, 2009 | 56 | 2009 |
| Cefepime-Aztreonam: a Unique Double β-Lactam Combination for Pseudomonas aeruginosa PD Lister, WE Sanders Jr, CC Sanders Antimicrobial agents and chemotherapy 42 (7), 1610-1619, 1998 | 53 | 1998 |
| Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs PD Lister, DJ Wolter, PA Wickman, MD Reisbig Journal of Antimicrobial Chemotherapy 57 (5), 999-1003, 2006 | 47 | 2006 |
| β‐Lactamase Inhibitor Combinations with Extended‐Spectrum Penicillins: Factors Influencing Antibacterial Activity against Enterobacteriaceae and Pseudomonas aeruginosa PD Lister Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 20 (9P2 …, 2000 | 47 | 2000 |
| Granulocyte colony-stimulating factor protects control rats but not ethanol-fed rats from fatal pneumococcal pneumonia PD Lister, MJ Gentry, LC Preheim Journal of Infectious Diseases 168 (4), 922-926, 1993 | 45 | 1993 |
